Blennow K - Search Results

1

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.

Milà-Alomà M, Shekari M, Salvadó G, Gispert JD, Arenaza-Urquijo EM, Operto G, Falcon C, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, Sánchez-Benavides G, González-de-Echávarri JM, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Simon M, Kollmorgen G, Zetterberg H, Blennow K, Suárez-Calvet M, Molinuevo JL; ALFA study. Milà-Alomà M, et al. Among authors: blennow k. Alzheimers Res Ther. 2021 Jul 27;13(1):134. doi: 10.1186/s13195-021-00863-y. Alzheimers Res Ther. 2021. PMID: 34315519 Free PMC article. Clinical Trial.

2

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

3

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

4

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Johansson A, et al. Among authors: blennow k. Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18. Hum Genet. 2004. PMID: 15034781

5

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. Prince JA, et al. Among authors: blennow k. Neurology. 2004 Jun 8;62(11):2116-8. doi: 10.1212/01.wnl.0000128088.08695.05. Neurology. 2004. PMID: 15184629

6

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.

Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2004 Sep 2;367(2):194-6. doi: 10.1016/j.neulet.2004.06.001. Neurosci Lett. 2004. PMID: 15331151

7

Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results.

Zetterberg H, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurol Sci. 2004 Dec;25(5):301-2. doi: 10.1007/s10072-004-0358-5. Neurol Sci. 2004. PMID: 15624089 No abstract available.

8

Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.

Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K. Rüetschi U, et al. Among authors: blennow k. Exp Neurol. 2005 Dec;196(2):273-81. doi: 10.1016/j.expneurol.2005.08.002. Epub 2005 Sep 8. Exp Neurol. 2005. PMID: 16154129

9

Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease.

Johansson A, Zetterberg H, Hampel H, Buerger K, Prince JA, Minthon L, Wahlund LO, Blennow K. Johansson A, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2005;20(6):367-74. doi: 10.1159/000088634. Epub 2005 Sep 29. Dement Geriatr Cogn Disord. 2005. PMID: 16192727

10

Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease.

Blennow K, Johansson A, Zetterberg H. Blennow K, et al. Int J Mol Med. 2005 Dec;16(6):1147-9. Int J Mol Med. 2005. PMID: 16273298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,323 results

Search Page

Filters